Advanced search
Publication Cover
Pharmacogenomics Volume 10, 2009 - Issue 12
Submit an article Journal homepage
138
Views
0
CrossRef citations to date
0
Altmetric
Special Report

Cytochrome P450 Loss-Of-Function Polymorphism Genotyping on the Agilent Bioanalyzer and Clinical Application

Irina PiatkovDiversity Health Institute Research Laboratory, SWAHS, Level 2 ICPMR, Westmead Hospital, Westmead, NSW 2145, Australia Tel.: +61 0298458755 fax: +61 [email protected]
,
Trudi JonesDiversity Health Institute Research Laboratory, SWAHS, Level 2 ICPMR, Westmead Hospital, Westmead, NSW 2145, Australia Tel.: +61 0298458755 fax: +61 [email protected]
&
Colin RochesterDiversity Health Institute Research Laboratory, SWAHS, Level 2 ICPMR, Westmead Hospital, Westmead, NSW 2145, Australia Tel.: +61 0298458755 fax: +61 [email protected]
Pages 1987-1994 | Published online: 03 Dec 2009

Bibliography

  • Bevan D : Genes, race and drugs.Clin. Invest. Med.27(1) , 5–6 (2004).
  • Kim K , JohnsonJA, DerendorfH: Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.J. Clin. Pharmacol.44(10) , 1083–1105 (2004).
  • Sistonen J , FuselliS, PaloJU, ChauhanN, PadhH, SajantilaA: Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.Pharmacogenet. Genomics19(2) , 170–179 (2009).
  • Takeuchi F , McginnisR, BourgeoisS : A genome-wide association study confirms vkorc1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet.5(3) , E1000433 (2009).
  • Wang JF , WeiDQ, ChouKC: Pharmacogenomics and personalized use of drugs.Curr. Top. Med. Chem.8(18) , 1573–1579 (2008).
  • Bhattacharyya S , RakhitR: Cytochrome P450 2C19 polymorphism and clopidogrel after mi.Lancet373(9670) , 1171; author reply 1172–1173 (2009).
  • Bijl MJ , van Schaik RH, Lammers LA : The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res. Treat.118(1) , 125–130 (2009).
  • Bijl MJ , VisserLE, van Schaik RH : Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in β-blocker users. Clin. Pharmacol. Ther.85(1) , 45–50 (2009).
  • Cavallari LH , LimdiNA: Warfarin pharmacogenomics.Curr. Opin. Mol. Ther.11(3) , 243–251 (2009).
  • De Leon J , ArranzMJ, RuanoG: Pharmacogenetic testing in psychiatry: a review of features and clinical realities.Clin. Lab. Med.28(4) , 599–617 (2008).
  • Ercan B , AyazL, CicekD, TamerL: Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis.Cell Biochem. Funct.26(3) , 309–313 (2008).
  • Hoskins JM , CareyLA, McleodHL: CYP2D6 and tamoxifen: DNA matters in breast cancer.Nat. Rev. Cancer9(8) , 576–586 (2009).
  • Klein TE , AltmanRB, ErikssonN : Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360(8) , 753–764 (2009).
  • Kobylecki CJ , JakobsenKD, HansenT, JakobsenIV, RasmussenHB, WergeT: CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case–control study.Neuropsychobiology59(4) , 222–226 (2009).
  • Loscher W , KlotzU, ZimprichF, SchmidtD: The clinical impact of pharmacogenetics on the treatment of epilepsy.Epilepsia50(1) , 1–23 (2009).
  • Mega JL , CloseSL, WiviottSD : Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med.360(4) , 354–362 (2009).
  • Sheu BS , FockKM: CYP2C19 genotypes and Helicobacter pylori eradication.J. Gastroenterol. Hepatol.23(8 Pt 1) , 1163 (2008).
  • Vormfelde SV , BrockmollerJ, BauerS : Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin. Pharmacol. Ther.86(1) , 54–61 (2009).
  • Wang JF , WeiDQ, ChouKC: Pharmacogenomics and personalized use of drugs.Curr. Top. Med. Chem.8(18) , 1573–1579 (2008).
  • Weiss J , Ten Hoevel MM, Burhenne J : CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J. Clin. Pharmacol.49(2) , 196–204 (2009).
  • Xu Y , SunY, YaoL : Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann. Oncol.19(8) , 1423–1429 (2008).
  • Yagihashi T , MizunoM, ChinoB : Effects of the CYP2D6*10 alleles and co-medication with cyp2d6-dependent drugs on risperidone metabolism in patients with schizophrenia. Hum. Psychopharmacol.24(4) , 301–308 (2009).
  • Zhao F , WangJ, YangY : Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for helicobacter pylori eradication: a meta-analysis. Helicobacter13(6) , 532–541 (2008).
  • Rebsamen MC , DesmeulesJ, DaaliY : The amplichip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J.9(1) , 34–41 (2009).
  • Chetty M , MurrayM: CYP-mediated clozapine interactions: how predictable are they?Curr. Drug Metab.8(4) , 307–313 (2007).
  • Faisal I , LindenmayerJP, TaintorZ, CancroR: Clozapine-benzodiazepine interactions.J. Clin. Psychiatry58(12) , 547–548 (1997).
  • Borentain S , MilletB, OlieJP: Cardiac risk at the onset of treatment in patients treated with benzodiazepines and clozapine.Eur. Psychiatry17(7) , 419–420 (2002).
  • Jackson CW , MarkowitzJS, BrewertonTD: Delirium associated with clozapine and benzodiazepine combinations.Ann. Clin. Psychiatry7(3) , 139–141 (1995).
  • Klimke A , KlieserE: Sudden death after intravenous application of lorazepam in a patient treated with clozapine.Am. J. Psychiatry151(5) , 780 (1994).
  • Frommer DA , KuligKW, MarxJA, RumackB: Tricyclic antidepressant overdose. A review.JAMA257(4) , 521–526 (1987).
  • Coutts RT : Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.J. Psychiatry Neurosci.19(1) , 30–44 (1994).
  • Bryant SG , FisherS, KlugeRM: Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system.J. Clin. Psychopharmacol.7(2) , 78–82 (1987).
  • Billups SJ , DelateT, DuganD: Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations.Pharmacoepidemiol. Drug Saf.18(3) , 253–257 (2009).
  • Lee SY , KiCS, HongKS, KimJW: A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.J. Korean Med. Sci.19(5) , 750–752 (2004).
  • Joyce PR , MulderRT, LutySE, MckenzieJM, RaeAM: A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender.Acta Psychiatr. Scand.108(1) , 20–23 (2003).
  • Joyce PR , MulderRT, LutySE : Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust. NZ J. Psychiatry36(3) , 384–391 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.